Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN)
CUSIP: 92790C104
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, $0.01 par value per share
- Shares outstanding
- 102,220,000
- Total 13F shares
- 69,645,524
- Share change
- -1,181,668
- Total reported value
- $906,163,827
- Put/Call ratio
- 176%
- Price per share
- $13.01
- Number of holders
- 137
- Value change
- -$23,346,202
- Number of buys
- 86
- Number of sells
- 44
Quarterly Holders Quick Answers
What is CUSIP 92790C104?
CUSIP 92790C104 identifies VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92790C104:
Top shareholders of VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
9.2%
|
9,415,135
|
$164,859,014 | — | 31 Mar 2024 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
4.9%
|
5,031,420
|
$88,100,164 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
4.4%
|
4,488,615
|
$78,595,649 | — | 31 Mar 2024 | |
| VR Adviser, LLC |
13F
|
Company |
3.8%
|
3,882,671
|
$67,985,569 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
3.7%
|
3,812,630
|
$66,759,152 | — | 31 Mar 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
3.6%
|
3,657,099
|
$64,035,803 | — | 31 Mar 2024 | |
| Deep Track Capital, LP |
13F
|
Company |
3.4%
|
3,456,053
|
$60,515,488 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.2%
|
3,234,279
|
$56,632,226 | — | 31 Mar 2024 | |
| MAVERICK CAPITAL LTD |
13F
|
Company |
2.6%
|
2,692,414
|
$47,144,169 | — | 31 Mar 2024 | |
| Commodore Capital LP |
13F
|
Company |
1.9%
|
1,934,653
|
$33,875,774 | — | 31 Mar 2024 | |
| Fairmount Funds Management LLC |
13F
|
Company |
1.8%
|
1,845,813
|
$32,320,186 | — | 31 Mar 2024 | |
| Frazier Life Sciences Public Fund, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,505,200
|
$31,609,200 | — | 23 Sep 2021 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.7%
|
1,722,819
|
$30,166,561 | — | 31 Mar 2024 | |
| Vivo Capital, LLC |
13F
|
Company |
1.6%
|
1,678,207
|
$29,385,405 | — | 31 Mar 2024 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
1.3%
|
1,335,000
|
$23,375,850 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
1.3%
|
1,332,454
|
$23,331,270 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
1,164,272
|
$20,390,413 | — | 31 Mar 2024 | |
| Novo Holdings A/S |
13F
|
Company |
1.1%
|
1,100,000
|
$19,261,000 | — | 31 Mar 2024 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.1%
|
1,095,441
|
$19,181,172 | — | 31 Mar 2024 | |
| Yiheng Capital Management, L.P. |
13F
|
Company |
0.93%
|
948,130
|
$16,601,756 | — | 31 Mar 2024 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.87%
|
889,198
|
$15,569,857 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.75%
|
762,411
|
$13,349,817 | — | 31 Mar 2024 | |
| 5AM Venture Management, LLC |
13F
|
Company |
0.72%
|
736,595
|
$12,897,778 | — | 31 Mar 2024 | |
| Logos Global Management LP |
13F
|
Company |
0.68%
|
700,000
|
$12,257,000 | — | 31 Mar 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.68%
|
692,925
|
$12,133,117 | — | 31 Mar 2024 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.61%
|
625,000
|
$10,943,750 | — | 31 Mar 2024 | |
| Octagon Capital Advisors LP |
13F
|
Company |
0.61%
|
620,000
|
$10,856,200 | — | 31 Mar 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
0.6%
|
614,010
|
$10,751,315 | — | 31 Mar 2024 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
0.59%
|
605,816
|
$10,607,838 | — | 31 Mar 2024 | |
| Jonathan Violin |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
720,110
mixed-class rows
|
$10,099,005 | — | 02 Feb 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0.55%
|
562,541
|
$9,850,094 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.53%
|
543,140
|
$9,510,381 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.47%
|
475,733
|
$8,330,085 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.45%
|
462,680
|
$8,101,526 | — | 31 Mar 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.43%
|
438,922
|
$7,685,524 | — | 31 Mar 2024 | |
| EAGLE ASSET MANAGEMENT INC |
13F
|
Company |
0.43%
|
438,767
|
$7,573,118 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.41%
|
424,085
|
$7,425,728 | — | 31 Mar 2024 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.4%
|
408,887
|
$7,159,611 | — | 31 Mar 2024 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.38%
|
389,087
|
$6,812,912 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.37%
|
379,584
|
$6,646,516 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.34%
|
347,913
|
$6,091,957 | — | 31 Mar 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.33%
|
340,000
|
$5,953,400 | — | 31 Mar 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.31%
|
321,606
|
$5,631,328 | — | 31 Mar 2024 | |
| Scott Dunseth Myers |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
259,500
|
$5,449,500 | — | 12 Apr 2023 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.3%
|
304,400
|
$5,330,044 | — | 31 Mar 2024 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
0.29%
|
300,000
|
$5,253,000 | — | 31 Mar 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
0.27%
|
280,000
|
$4,902,800 | — | 31 Mar 2024 | |
| Cutter Capital Management, LP |
13F
|
Company |
0.27%
|
278,638
|
$4,878,951 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.26%
|
261,700
|
$4,582,000 | — | 31 Mar 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.24%
|
240,829
|
$4,216,916 | — | 31 Mar 2024 |
Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) as of Q2 2024
As of 30 Jun 2024,
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) was held by
137 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
69,645,524 shares.
The largest 10 holders included
FMR LLC, BlackRock Inc., Deep Track Capital, LP, VR Adviser, LLC, VANGUARD GROUP INC, MAVERICK CAPITAL LTD, Paradigm Biocapital Advisors LP, STATE STREET CORP, COMMODORE CAPITAL LP, and Novo Holdings A/S.
This page lists
137
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
134
Q2 2024 holders
137
Holder diff
3
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.